Cytokinetics, Incorporated (CYTK)
- Previous Close
67.00 - Open
66.88 - Bid 67.44 x 400
- Ask 67.58 x 200
- Day's Range
64.82 - 67.80 - 52 Week Range
25.98 - 110.25 - Volume
1,474,255 - Avg. Volume
2,077,622 - Market Cap (intraday)
7.064B - Beta (5Y Monthly) 0.68
- PE Ratio (TTM)
-- - EPS (TTM)
-5.45 - Earnings Date May 2, 2024 - May 6, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
95.06
Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure. The company also develops CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; CK-586, a small molecule cardiac myosin inhibitor, that is in Phase I clinical trial; and aficamten, a novel cardiac myosin inhibitor, which is in Phase III clinical trial for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy. Cytokinetics, Incorporated has a strategic alliance with Ji Xing Pharmaceuticals Limited. The company was incorporated in 1997 and is headquartered in South San Francisco, California.
www.cytokinetics.comRecent News: CYTK
Performance Overview: CYTK
Trailing total returns as of 4/19/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: CYTK
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: CYTK
Valuation Measures
Market Cap
7.01B
Enterprise Value
7.15B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
858.85
Price/Book (mrq)
--
Enterprise Value/Revenue
949.21
Enterprise Value/EBITDA
-15.65
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-33.73%
Return on Equity (ttm)
--
Revenue (ttm)
7.53M
Net Income Avi to Common (ttm)
-526.24M
Diluted EPS (ttm)
-5.45
Balance Sheet and Cash Flow
Total Cash (mrq)
614.82M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-261.36M
Research Analysis: CYTK
Analyst Price Targets
Fair Value
Analyst Recommendations
- Strong Buy
- Buy
- Hold
- Underperform
- Sell
Earnings
Research Reports: CYTK
CYTK: Lowering target price to $72.00
CYTOKINETICS INC has an Investment Rating of HOLD; a target price of $72.000000; an Industry Subrating of Low; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of High; and a Value Subrating of Low.
RatingNeutralPrice TargetCYTK: Raising target price to $79.00
CYTOKINETICS INC has an Investment Rating of HOLD; a target price of $79.000000; an Industry Subrating of Low; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of High; and a Value Subrating of Low.
RatingNeutralPrice TargetCYTK: What does Argus have to say about CYTK?
CYTOKINETICS INC has an Investment Rating of HOLD; a target price of $75.000000; an Industry Subrating of Low; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of High; a Growth Subrating of High; and a Value Subrating of Low.
RatingNeutralPrice TargetCYTK: Raising target price to $75.00
CYTOKINETICS INC has an Investment Rating of HOLD; a target price of $75.000000; an Industry Subrating of Low; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of High; a Growth Subrating of High; and a Value Subrating of Low.
RatingNeutralPrice Target